Pharmena S.A.
PHR.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.27 | -0.08 | 1.20 |
| FCF Yield | 0.00% | -3.03% | -19.47% | -0.18% |
| EV / EBITDA | 0.26 | -39.00 | -113.76 | -43.61 |
| Quality | ||||
| ROIC | -7.33% | -7.73% | -5.58% | -1.14% |
| Gross Margin | 84.77% | -175.39% | 76.59% | 85.23% |
| Cash Conversion Ratio | 1.19 | 1.31 | 1.75 | 0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -41.37% | -56.60% | -68.14% | -75.85% |
| Free Cash Flow Growth | 15.70% | 89.89% | -12,576.92% | 64.38% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | 0.01 | 1.40 | 1.59 |
| Interest Coverage | -87.44 | 0.00 | -95.14 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.09 | 1.53 | 0.14 | 0.02 |
| Cash Conversion Cycle | 802.32 | 79.56 | 310.90 | 1,815.42 |